Organization

BTG Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: London United Kingdom (1991)

Status: Acquired by Boston Scientific Corporation (2018)

Organization Overview

First Clinical Trial

2000

NCT00219791

First Marketed Drug

1993

abiraterone (zytiga)

First NDA Approval

2000

crotalidae polyvalent immune fab (ovine) (CroFab)

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (8)

abiraterone (zytiga) (1993)

crotalidae polyvalent immune fab (ovine) (CroFab) (2000 NDA)

digoxin immune fab (ovine) (DigiFab) (2001)

glucarpidase (voraxaze) (2012)

hydroxocobalamin (cyanokit) (2006)

polidocanol (asclera) (2013)

potassium iodide (thyro-block) (2002)

uridine (2015)

Drugs in Phase 4 Trials (3)

Key: BTG (2) Acquired (1)

alteplase (Activase) (3 trials)

crotalidae polyvalent immune fab (ovine) (CroFab) (1 trial)

polidocanol (asclera) (9 trials)

Drugs in Phase 3 Trials (4)

Key: BTG (1) Acquired (3)

90-yttrium (3 trials)

heparin (liquaemin) (1 trial)

sodium chloride (2 trials)

sorafenib (nexavar) (2 trials)

Drugs in Phase 2 Trials (22)

Key: BTG (11) Acquired (11)

bevacizumab (avastin) (1 trial)

bgc20-0582 (1 trial)

bgc20-1531 (1 trial)

brivudine phosphoramidate (1 trial)

caricotamide (1 trial)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (1 trial)

covaccine (2 trials)

digoxin immune fab (ovine) (DigiFab) (1 trial)

doxorubicin (Doxil) (2 trials)

durvalumab (imfinzi) (2 trials)

fluorouracil (efudex) (5 trials)

glucagon-like peptide-1 (1 trial)

glucarpidase (voraxaze) (8 trials)

irinotecan (Camptosar) (5 trials)

lactose (1 trial)

leucovorin (5 trials)

oxaliplatin (eloxatin) (3 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (2 trials)

pleneva (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (8)

Key: BTG (6) Acquired (2)

68ga-maa (1 trial)

cm3.1-ac100 (3 trials)

everolimus (zortress) (1 trial)

methotrexate (1 trial)

naltrexone (revia) (1 trial)

survivin-peptide double loaded dendritic cells (1 trial)

tc 99m maa (1 trial)

vandetanib (caprelsa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Brain Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Cardiovascular Diseases (Phase 2)

Cerebral Hemorrhage (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Eclampsia (Phase 2)

Esophageal Neoplasms (Phase 2)

Gastroesophageal Reflux (Phase 4)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Hemoptysis (Phase 1)

Hemorrhage (Phase 2)

Hyperplasia (Phase 1)

Hypertension (Phase 2)

Leg Ulcer (Phase 4)

Lice Infestations (Phase 2)

Liver Neoplasms (Phase 1)

Migraine Disorders (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Osteosarcoma (Phase 2)

Parasitic Diseases (Phase 2)

Pre-Eclampsia (Phase 2)

Prostatic Hyperplasia (Phase 1)

Sclerosis (Phase 2)

Snake Bites (Phase 4)

Ulcer (Phase 4)

Varicose Ulcer (Phase 4)

Varicose Veins (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 54
# of Trial APIs: 37